1219 related articles for article (PubMed ID: 28552987)
1. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
4. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S; Turley SJ; Nickles D; Castiglioni A; Yuen K; Wang Y; Kadel EE; Koeppen H; Astarita JL; Cubas R; Jhunjhunwala S; Banchereau R; Yang Y; Guan Y; Chalouni C; Ziai J; Şenbabaoğlu Y; Santoro S; Sheinson D; Hung J; Giltnane JM; Pierce AA; Mesh K; Lianoglou S; Riegler J; Carano RAD; Eriksson P; Höglund M; Somarriba L; Halligan DL; van der Heijden MS; Loriot Y; Rosenberg JE; Fong L; Mellman I; Chen DS; Green M; Derleth C; Fine GD; Hegde PS; Bourgon R; Powles T
Nature; 2018 Feb; 554(7693):544-548. PubMed ID: 29443960
[TBL] [Abstract][Full Text] [Related]
5. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Teo MY; Seier K; Ostrovnaya I; Regazzi AM; Kania BE; Moran MM; Cipolla CK; Bluth MJ; Chaim J; Al-Ahmadie H; Snyder A; Carlo MI; Solit DB; Berger MF; Funt S; Wolchok JD; Iyer G; Bajorin DF; Callahan MK; Rosenberg JE
J Clin Oncol; 2018 Jun; 36(17):1685-1694. PubMed ID: 29489427
[TBL] [Abstract][Full Text] [Related]
6. Single-cell analysis reveals clonally expanded tumor-associated CD57
Fehlings M; Kim L; Guan X; Yuen K; Tafazzol A; Sanjabi S; Zill OA; Rishipathak D; Wallace A; Nardin A; Ma S; Milojkovic A; Newell EW; Mariathasan S; Yadav M
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981786
[TBL] [Abstract][Full Text] [Related]
7. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
8. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
9. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Lehmann BD; Abramson VG; Dees EC; Shah PD; Ballinger TJ; Isaacs C; Santa-Maria CA; An H; Gonzalez-Ericsson PI; Sanders ME; Newsom KC; Abramson RG; Sheng Q; Hsu CY; Shyr Y; Wolff AC; Pietenpol JA
JAMA Oncol; 2024 Feb; 10(2):193-201. PubMed ID: 38095878
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
12. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
13. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
15. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
16. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV; Galsky MD; Rosenberg JE; Powles T; Petrylak DP; Bellmunt J; Loriot Y; Necchi A; Hoffman-Censits J; Perez-Gracia JL; Dawson NA; van der Heijden MS; Dreicer R; Srinivas S; Retz MM; Joseph RW; Drakaki A; Vaishampayan UN; Sridhar SS; Quinn DI; Durán I; Shaffer DR; Eigl BJ; Grivas PD; Yu EY; Li S; Kadel EE; Boyd Z; Bourgon R; Hegde PS; Mariathasan S; Thåström A; Abidoye OO; Fine GD; Bajorin DF;
Lancet; 2017 Jan; 389(10064):67-76. PubMed ID: 27939400
[TBL] [Abstract][Full Text] [Related]
18. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
20. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O'Hear C; Fassò M; Molinero L; Schmid P
JAMA Oncol; 2019 Jan; 5(1):74-82. PubMed ID: 30242306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
